# A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

> **NCT07172802** · PHASE1,PHASE2 · RECRUITING · sponsor: **GI Innovation, Inc.** · enrollment: 76 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Metastatic Solid Tumor
- Non-small Cell Lung Cancer (NSCLC)
- Head and Neck (HNSCC)
- Pancreatic Cancer
- Renal Cell Carcinoma (RCC)

## Interventions

- **DRUG:** GI-108

## Key facts

- **NCT ID:** NCT07172802
- **Lead sponsor:** GI Innovation, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-22
- **Primary completion:** 2027-02
- **Final completion:** 2027-09
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07172802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07172802, "A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07172802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*